Translational medicine for acute lung injury

Jianguo Zhang; Yumeng Guo; Michael Mak; Zhimin Tao

doi:10.1186/s12967-023-04828-7

Translational medicine for acute lung injury

J Transl Med. 2024 Jan 5;22(1):25. doi: 10.1186/s12967-023-04828-7.

Authors

Jianguo Zhang^#¹, Yumeng Guo^#², Michael Mak³, Zhimin Tao^{4

5

6

7}

Affiliations

¹ Department of Emergency Medicine, The Affiliated Hospital, Jiangsu University, Zhenjiang, 212001, Jiangsu, China.
² Jiangsu Key Laboratory of Medical Science and Laboratory Medicine, Department of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, 212013, Jiangsu, China.
³ Department of Biomedical Engineering, School of Engineering and Applied Science, Yale University, New Haven, 06520, USA.
⁴ Department of Emergency Medicine, The Affiliated Hospital, Jiangsu University, Zhenjiang, 212001, Jiangsu, China. jsutao@ujs.edu.cn.
⁵ Jiangsu Key Laboratory of Medical Science and Laboratory Medicine, Department of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, 212013, Jiangsu, China. jsutao@ujs.edu.cn.
⁶ Department of Biomedical Engineering, School of Engineering and Applied Science, Yale University, New Haven, 06520, USA. jsutao@ujs.edu.cn.
⁷ Zhenjiang Key Laboratory of High Technology Research on Exosomes Foundation and Transformation Application, School of Medicine, Jiangsu University, Zhenjiang, 212013, Jiangsu, China. jsutao@ujs.edu.cn.

^# Contributed equally.

Abstract

Acute lung injury (ALI) is a complex disease with numerous causes. This review begins with a discussion of disease development from direct or indirect pulmonary insults, as well as varied pathogenesis. The heterogeneous nature of ALI is then elaborated upon, including its epidemiology, clinical manifestations, potential biomarkers, and genetic contributions. Although no medication is currently approved for this devastating illness, supportive care and pharmacological intervention for ALI treatment are summarized, followed by an assessment of the pathophysiological gap between human ALI and animal models. Lastly, current research progress on advanced nanomedicines for ALI therapeutics in preclinical and clinical settings is reviewed, demonstrating new opportunities towards developing an effective treatment for ALI.

Keywords: Acute lung injury; Acute respiratory distress syndrome; Animal model; Drug delivery; Nanomedicine; Therapy.

Publication types

Review

MeSH terms

Acute Lung Injury* / drug therapy
Animals
Humans
Models, Animal
Translational Science, Biomedical*